

Diese Meldung kann unter <http://www.presseportal.de/pm/16998/1161436/new-studies-confirm-the-benefits-of-dapoxetine-as-a-treatment-of-premature-ejaculation> abgerufen werden.



## New Studies Confirm the Benefits of Dapoxetine as a Treatment of Premature Ejaculation

27.03.2008 - 13:58 Uhr, Janssen-Cilag GmbH

European Association of Urology (EAU), MILAN, March 27 (ots/PRNewswire)  
-- - Pivotal Efficacy Data Reinforced by Female Partners; Robust Safety Data Presented

New data presented for the first time today at EAU demonstrate the benefits for men with premature ejaculation (PE) and their partners when treated with dapoxetine, the first oral pharmaceutical treatment to be developed specifically for PE(1).

The multinational phase III clinical trial enrolled over one thousand men and their female partners from 22 countries (including 16 European countries, Israel, South Africa, Canada, Mexico, Brazil and Argentina) to measure improvement of sexual functioning while taking 30mg or 60mg of dapoxetine (taken 1 to 3 hours prior to intercourse) versus placebo. Previously reported data showed significant improvements in men with PE treated with dapoxetine 30mg and 60mg across all measures of PE versus placebo(2).

The data presented today from female partners reinforce the beneficial impact of dapoxetine treatment, demonstrating significant improvement in all four pre-defined endpoints for partners of men treated with dapoxetine 30mg or 60mg versus placebo over a 25-week period(1):

- Perception of the Man's control over ejaculation: At baseline, fewer than 5% of women reported that their perception of their partner's control was "good" or "very good". This percentage increased to 24.7% and 32.4% with dapoxetine 30mg and 60mg respectively (vs 14.5% with placebo; p

Originaltext:

Janssen-Cilag GmbH

Pressemappe:

<http://www.presseportal.de/pm/16998/janssen-cilag-gmbh>

Pressemappe als RSS:

[http://presseportal.de/rss/pm\\_16998.rss2](http://presseportal.de/rss/pm_16998.rss2)